LENZ Therapeutics, Inc. (LENZ)

Market Cap	300.38M -57.6%
Revenue (ttm)	19.09M
Net Income	-82.13M
EPS	-2.85
Shares Out	31.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	958,394
Open	9.82
Previous Close	9.90
Day's Range	9.46 - 10.21
52-Week Range	8.25 - 50.40
Beta	2.30
Analysts	Strong Buy
Price Target	45.60 (+375.99%)
Earnings Date	May 6, 2026

About LENZ

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 152
• Stock Exchange: NASDAQ
• Ticker Symbol: LENZ
• Website: https://www.lenz-tx.com

Analyst Summary

According to 5 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price target is $45.6, which is an increase of 375.99% from the latest price.

Price Target

$45.6

(375.99% upside)

Analyst Consensus: Strong Buy